The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects

Biochemical Pharmacology

Volumn 84, Issue 2, 2012, Pages 163-171

  Cassinelli, Giuliana ^a   Zuco, Valentina ^a   Petrangolini, Giovanna ^a   De Cesare, Michelandrea ^a   Tortoreto, Monica ^a   Lanzi, Cinzia ^a   Cominetti, Denis ^a   Zaffaroni, Nadia ^a   Orlandi, Augusto ^b   Passeri, Daniela ^b   Meco, Daniela ^c   Di Francesco, Angela Maria ^c   Riccardi, Riccardo ^c   Bucci, Federica ^d   Pisano, Claudio ^d   Zunino, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d Sigma Tau SpA   (Italy)

Author keywords

Antiangiogenesis; Antitumor activity; Camptothecin derivative; Pediatric sarcoma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BEVACIZUMAB; CXCL16 CHEMOKINE; DNA TOPOISOMERASE; IRINOTECAN; NAMITECAN; SECONDARY LYMPHOID TISSUE CHEMOKINE; SUNITINIB; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILDHOOD CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG EFFICACY; EMBRYONAL RHABDOMYOSARCOMA; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; UNDIFFERENTIATED CARCINOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHEMOKINE CCL2; CHEMOKINES, CXC; DNA TOPOISOMERASES, TYPE I; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; INDOLES; MICE; MICE, NUDE; PYRROLES; RECEPTORS, SCAVENGER; RHABDOMYOSARCOMA; SARCOMA; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861234062     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.04.005     Document Type: Article

References (28)

1. L.M. Wagner Oral irinotecan for treatment of pediatric solid tumors: ready for prime time Pediatr Blood Cancer 54 2010 661 662
2. G. Vassal, D. Couanet, E. Stockdale, A. Geoffray, B. Geoerger, and D. Orbach Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group J Clin Oncol 25 2007 356 361
3. A.S. Pappo, E. Lyden, P. Breitfeld, S.S. Donaldson, E. Wiener, and D. Parham Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group J Clin Oncol 25 2007 362 369
4. D.A. Casey, L.H. Wexler, M.S. Merchant, A.J. Chou, P.R. Merola, and A.P. Price Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience Pediatr Blood Cancer 53 2009 1029 1034
5. M. Zucchetti, D. Meco, A.M. Di Francesco, T. Servidei, V. Patriarca, and G. Cusano Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts Cancer Chemother Pharmacol 66 2010 635 641
6. S. Dallavalle, A. Ferrari, B. Biasotti, L. Merlini, S. Penco, and G. Gallo Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity J Med Chem 44 2001 3264 3274
7. C. Pisano, M. De Cesare, G.L. Beretta, V. Zuco, G. Pratesi, and S. Penco Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968 Mol Cancer Ther 7 2008 2051 2059
8. C. Pisano, V. Zuco, M. De Cesare, V. Benedetti, L. Vesci, and R. Foderà Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968 Eur J Cancer 44 2008 1332 1340
9. P. Huang, P.L. Olive, and R.E. Durand Use of the comet assay for assessment of drug resistance and its modulation in vivo Brit J Cancer 77 1998 412 416
10. G.L. Beretta, and F. Zunino Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity Biochem Pharmacol 74 2007 1437 1444
11. H. Carol, P.J. Houghton, C.L. Morton, E.A. Kolb, R. Gorlick, and C.P. Reynolds Initial testing of topotecan by the Pediatric Preclinical Testing Program Pediatric Blood Cancer 54 2010 707 715
12. M. Kilic, H. Kasperczyk, S. Fulda, and K.-M. Debatin Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance Oncogene 26 2007 2027 2038
13. G. Petrangolini, G. Pratesi, M. De Cesare, R. Supino, C. Pisano, and M. Marcellini Antiangiogenic effects of the novel camptothecin ST1481 (Gimatecan) in human tumor xenografts Mol Cancer Res 1 2003 863 870
14. H. Kamiyama, S. Takano, K. Tsuboi, and A. Matsumura Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells J Cancer Res Clin Oncol 131 2005 205 213
15. M. De Cesare, G.L. Beretta, S. Tinelli, V. Benedetti, G. Pratesi, and S. Penco Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series Biochem Pharmacol 73 2007 656 664
16. S. Dalal, A.M. Berry, C.J. Cullilane, D.C. Mangham, R. Grimer, and I.J. Lewis Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family Clin Cancer Res 11 2005 2364 2378
17. S. Kamura, Y. Matsumoto, J.-I. Fukushi, T. Fujiwara, K. Iida, and Y. Okada Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-RacI pathway Brit J Cancer 103 2010 370 381
18. M. Wachtel, and B.W. Schafer Targets for cancer therapy in childhood sarcomas Cancer Treat Rev 36 2010 318 327
19. B. Onnis, A. Rapisarda, and G. Melillo Development of HIF-1 inhibitors for cancer therapy J Cell Mol Med 13 2009 2780 2786
20. K. Guo, V. Gokhale, L.H. Hurley, and D. Sun Intramolecularly folded G-quadruplex and i-motif structures in the proximal promoter of the vascular endothelial growth factor gene Nucleic Acids Res 36 2008 4598 4608
21. M.R. Kang, M.T. Muller, and I.K. Chung Telomeric DNA damage by topoisomerase I J Biol Chem 279 2004 12535 12541
22. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill Cancer-related inflammation Nature 454 2008 436 444
23. R.M. Wadkins, D. Bearss, G. Manikumar, M.C. Wani, M.E. Wall, and D.D. Von Hoff Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I Cancer Res 64 2004 6679 6683
24. V. Zuco, R. Supino, E. Favini, M. Tortoreto, R. Cincinelli, and A.C. Croce Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma Biochem Pharmacol 79 2010 535 541
25. M. Duvvuri, S. Konkar, K. Ho Hong, B.S.J. Blagg, and J.P. Krise A new approach for enhancing differential, selectivity of drugs to cancer cells ACS Chem Biol 1 2006 309 315
26. K. Ganjoo, and C. Jacobs Antiangiogenesis agents in the treatment of soft tissue sarcomas Cancer 116 2010 1177 1183
27. H.R. Park, K. Min, H.S. Kim, W.W. Jung, and Y.K. Park Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas Pathol Res Pract 204 2008 575 582
28. M.F. Gee, R. Tsuchida, C. Eichler-Jonsson, B. Das, S. Barichel, and D. Malkin Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid Oncogene 24 2005 8025 8037